Does rTMS Induce Synaptic Plasticity?
Reason given: We did not receive grant funding for this study.
Key facts
- Where
- Palo Alto and Stanford, United StatesSee the 2 sites
- Phase
- Phase 1
Where in United States
- VA Palo Alto Health Care SystemPalo Alto, United StatesNo longer taking part
- Stanford UniversityStanford, United StatesNo longer taking part
Trial details
- Who runs it
- Davidzon, Guido, M.D.
- Trial code
- NCT04311619
- Record updated
- 2 December 2024
- Original description
The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to investigate the effect of repetitive transcranial magnetic stimulation (rTMS) on synaptic plasticity. UCB-J has been validated as a marker for synaptic density. We will use this tracer to examine if rTMS leads to changes in synaptic plasticity, specifically changes in synaptic density, in individuals receiving rTMS for MDD. If rTMS is proven effective for increasing synaptic plasticity, there is a significant potential of a new applicable treatment for a variety of diseases that affect brain physiology.Read full original descriptionShow less
Does Repetitive Transcranial Magnetic Stimulation (rTMS) Induce Synaptic Plasticity?
The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to investigate the effect of repetitive transcranial magnetic stimulation (rTMS) on synaptic plasticity. UCB-J has been validated as a marker for synaptic density. We will use this tracer to examine if rTMS leads to changes in synaptic plasticity, specifically changes in synaptic density, in individuals receiving rTMS for MDD. If rTMS is proven effective for increasing synaptic plasticity, there is a significant potential of a new applicable treatment for a variety of diseases that affect brain physiology.
Inclusion: 18-70 years in age; U.S. Veteran; Diagnosis of MDD; On a stable medication regimen for at least two weeks prior to testing; Stable social environment and housing to enable regular attendance at clinic visits; Ability to undergo cognitive testing, clinical assessments, and PET/MR scans; Stable medical health; Will undergo rTMS treatment for MDD at the VA Palo Alto; Able to complete a PET-MR scan without the use of sedation.
Exclusion: Contraindication to MR scanning, including magnetic-resonance incompatible metal or hardware including pacemakers, cochlear implants, and bullets near a critical organ; Major medical neurological illness or significant head trauma; History of or current claustrophobia; Acute or unstable chronic medical illness that would affect participation or compliance with study procedures, e.g. unstable angina; Unstable psychiatric symptoms that precludes consistent participation in the study, e.g. active current suicidal intent or plan, severe psychosis; Active substance use within three months of testing; IQ < 70; Pregnancy or breastfeeding; Weight > 350 lbs or a large body habitus that MR scanner cannot accommodate; Inability to comply with basic study requirements such as following directions and punctuality; Inability to undergo PET/MR scan, e.g. claustrophobia, presence of ferromagnetic objects in subject's body.